Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation
Kaushal Asrani, … , Michael Skaro, Tamara L. Lotan
Kaushal Asrani, … , Michael Skaro, Tamara L. Lotan
Published September 17, 2019
Citation Information: J Clin Invest. 2019;129(12):5584-5599. https://doi.org/10.1172/JCI128287.
View: Text | PDF
Research Article Metabolism Oncology

mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation

  • Text
  • PDF
Abstract

The microphthalmia family of transcription factors (MiT/TFEs) controls lysosomal biogenesis and is negatively regulated by the nutrient sensor mTORC1. However, the mechanisms by which cells with constitutive mTORC1 signaling maintain lysosomal catabolism remain to be elucidated. Using the murine epidermis as a model system, we found that epidermal Tsc1 deletion resulted in a phenotype characterized by wavy hair and curly whiskers, and was associated with increased EGFR and HER2 degradation. Unexpectedly, constitutive mTORC1 activation with Tsc1 loss increased lysosomal content via upregulated expression and activity of MiT/TFEs, whereas genetic deletion of Rheb or Rptor or prolonged pharmacologic mTORC1 inactivation had the reverse effect. This paradoxical increase in lysosomal biogenesis by mTORC1 was mediated by feedback inhibition of AKT, and a resulting suppression of AKT-induced MiT/TFE downregulation. Thus, inhibiting hyperactive AKT signaling in the context of mTORC1 loss-of-function fully restored MiT/TFE expression and activity. These data suggest that signaling feedback loops work to restrain or maintain cellular lysosomal content during chronically inhibited or constitutively active mTORC1 signaling, respectively, and reveal a mechanism by which mTORC1 regulates upstream receptor tyrosine kinase signaling.

Authors

Kaushal Asrani, Sanjana Murali, Brandon Lam, Chan-Hyun Na, Pornima Phatak, Akshay Sood, Harsimar Kaur, Zoya Khan, Michaël Noë, Ravi K. Anchoori, C. Conover Talbot Jr., Barbara Smith, Michael Skaro, Tamara L. Lotan

×

Figure 8

Inhibition of hyperactive AKT in mTORC1-inhibited cells rescues autophagy/lysosomal biogenesis and downregulates EGFR expression.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of hyperactive AKT in mTORC1-inhibited cells rescues autophag...
(A) Immunoblotting showing increased expression of lysosomal, autophagy, and MiT/TFE proteins in Rptor-cre keratinocytes treated with MK2206 (1 μM, 5 μM; 8 hours). Ctsb, LAMP1, and tubulin are noncontemporaneous immunoblots of the same biological replicate, while all other blots are contemporaneous parallel immunoblots of the same biological replicate. (B) LAMP1 immunostaining showing expansion and perinuclear localization of lysosomes in empty and Rptor-cre keratinocytes treated with MK2206 (5 μM, 8 hours), compared with DMSO controls. Scale bar: 50 μm. (C) MK2206-treated Rptor-cre keratinocytes show increased LysoTracker Red fluorescence compared with DMSO controls. Scale bar: 40 μm. (D) Electron micrographs showing increased presence of autophagic vesicles (black arrows) in MK2206-treated Rptor-cre keratinocytes, compared with DMSO controls. Scale bar: 2 μm. (E) MiT/TFE proteins are increased in nuclear-fraction immunoblots of MK2206-treated Rptor-cre keratinocytes (1, 5 μM; 8 hours). Lamin A/C and fibrillarin are used as loading controls. (F) MK2206 treatment of Rptor-cre keratinocytes increases 4X-CLEAR luciferase reporter activity. Renilla is used to normalize for luciferase activity (r = 4; error bars represent SD; P values by Student’s t test). (G) Immunoblotting showing decreased expression of EGFR and HER2 in Rptor-cre keratinocytes treated with MK2206/AZD5363 for 24 hours. (H) Immunoblotting showing increased expression of lysosomal markers and MiT/TFE proteins with downregulation of EGFR expression in Rptor-cre keratinocytes treated with AKT1/2 siRNA. (I) Immunoblotting showing decreased expression of lysosomal markers and MiT/TFE proteins with upregulation of EGFR and HER2 expression in Tsc1-cre keratinocytes infected with Myr-AKT1 or Myr-AKT2 adenovirus.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts